Red Clover

Red clover (Trifolium pratense) contains natural coumarin compounds and isoflavones (biochanin A, formononetin) that inhibit platelet aggregation and may potentiate anticoagulant effects. A published case report documented warfarin-like coagulopathy (elevated INR, haematuria, ecchymosis) in a patient consuming red clover and alfalfa tea without taking warfarin, suggesting intrinsic anticoagulant activity.

Monitor INR closely when red clover is started or discontinued in patients on warfarin. Patients should be informed of signs of bleeding. If INR destabilises or bleeding occurs, discontinue red clover immediately and reassess anticoagulant dose.

Red clover isoflavones act as phytoestrogens with agonist activity at estrogen receptors (ER-α and ER-β), potentially competing with tamoxifen for receptor binding. In animal and in vitro studies, red clover treatment significantly downregulated CYP1A1, CYP2B2, and CYP3A2, enzymes involved in tamoxifen activation and metabolism. This may antagonise tamoxifen anti-tumour efficacy in hormone-sensitive breast cancer.

Advise patients with hormone receptor-positive breast cancer on tamoxifen to strictly avoid red clover supplements. This is a clinically important interaction in oncology. If patients request phytoestrogens for menopausal symptoms, discuss safer alternatives with the oncology team.

Red clover isoflavones (formononetin, biochanin A, genistein, daidzein) bind ER-α and ER-β and act as phytoestrogens; concurrent use with exogenous estrogen therapy produces additive estrogenic receptor stimulation. This may increase the risk of endometrial hyperplasia, venous thromboembolism, and hormone-sensitive cancer progression.

Discourage concurrent use of red clover supplements with HRT or combined oral contraceptives, especially in women at elevated risk of thromboembolic disease or hormone-sensitive cancers. If patients insist on combination, monitor for estrogenic adverse effects (breast tenderness, edema, abnormal uterine bleeding).

In vitro studies demonstrate that red clover isoflavones (biochanin A, formononetin) inhibit CYP2C9 activity. This could theoretically increase plasma levels of CYP2C9-metabolised drugs (phenytoin, S-warfarin, celecoxib). A clinical pharmacokinetic probe drug study (120 mg isoflavones/day for 2 weeks) found no statistically significant interactions with tolbutamide (CYP2C9) or caffeine (CYP1A2), suggesting low clinical risk at standard doses.

Clinical significance is low at standard supplemental doses (up to 120 mg isoflavones/day). However, monitor for signs of increased drug exposure with narrow-therapeutic-index CYP2C9 substrates in patients using higher doses. Check phenytoin levels if red clover is combined with phenytoin therapy.

Red clover isoflavones may improve insulin sensitivity and exert mild hypoglycemic effects through modulation of adiponectin production and glucose metabolism pathways, potentially enhancing the glucose-lowering effects of antidiabetic agents.

Monitor blood glucose when red clover is added to an antidiabetic regimen. Dose adjustments of antidiabetic medications may be needed. Educate patients on hypoglycemia recognition.

Red clover isoflavones have demonstrated weak anti-inflammatory effects and may interact with glucocorticoid receptor signalling pathways. Additionally, the estrogenic properties of red clover may influence cortisol binding globulin and adrenal hormone metabolism in patients on corticosteroid therapy.

Low-risk combination at standard doses. No dose adjustment required. Advise patients to disclose red clover use to their prescribers, especially when on long-term corticosteroid therapy.